Insys Therapeutics Inc (INSY) is Reiterated by RBC Capital Mkts to Outperform, Lowers Price Target to $ 26

Insys Therapeutics Inc (INSY) was Reiterated by RBC Capital Mkts to “Outperform” while Lowering the Price Target of the company shares to $ 26 from a previous price target of $32 . RBC Capital Mkts advised their investors in a research report released on Sep 22, 2016.

On the company’s financial health, Insys Therapeutics Inc reported $0.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $0.07. The company had revenue of $67.10 million for the quarter, compared to analysts expectations of $66.94 million. The company’s revenue was down -13.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.21 EPS.

Insys Therapeutics Inc opened for trading at $13.8 and hit $13.91 on the upside on Tuesday, eventually ending the session at $13.75, with a gain of 1.33% or 0.18 points. The heightened volatility saw the trading volume jump to 6,13,233 shares. Company has a market cap of $984 M.

In a different news, on Aug 16, 2016, Theodore H Stanley (director) sold 15,000 shares at $18.02 per share price. According to the SEC, on Aug 12, 2016, Patrick Fourteau (director) sold 15,000 shares at $18.46 per share price. On Aug 12, 2016, John N Kapoor (CEO) purchased 5,700 shares at $18.57 per share price, according to the Form-4 filing with the securities and exchange commission.

Insys Therapeutics Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule a generic equivalent to Marinol (dronabinol) an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. The Company’s lead product candidate is Dronabinol oral solution an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.

Insys Therapeutics Inc

Leave a Reply

Insys Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Insys Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.